C-X-C Chemokine Receptor-3 as a Diagnostic Biomarker in Patients with Rheumatoid Arthritis | ||||
| Journal of Advanced Medical and Pharmaceutical Research | ||||
| Article 5, Volume 2, Issue 1, March 2021, Page 33-38 PDF (386.09 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jampr.2021.58127.1014 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Amany Hamed  1; Hanan Hassan Omar2; Samah Ismail Nasef 3; Mohamed Salama4; Azza Abdalla5
| ||||
| 1Chemistry, Faculty of Science, Sohag University, Sohag, Egypt | ||||
| 2Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt | ||||
| 3Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Suez Canal University, Ismailia, Egypt | ||||
| 4Department of Chemistry, Faculty of Science, Sohag University, Sohag, Egypt | ||||
| 5Department of Chemistry, Faculty of Science, Suez Canal University, Ismailia, Egypt | ||||
| Abstract | ||||
| Background: RA is a chronic and systemic inflammatory disease described by synovial inflammation and the progressive destruction of joint ligaments and bones. CXCR3 is a seven-transmembrane G-protein-coupled chemokine receptor that has been appeared to play a vital role in a variety of inflammatory and immunological responses. We aimed to evaluate the utility of serum CXCR3 levels in the diagnosis, monitor, and follow-up of RA patients. Methods: Sixty RA patients were divided into; 30 early RA patients with disease duration < 2 years and 30 longstanding RA patients with disease duration ≥ 2 years. Thirty healthy subjects were recruited as a control group. Medical history and clinical data were taken. All the patients were assessed for ESR, CRP, RF, Anti-CCP, and CXCR3 serum levels. Results: Serum CXCR3 level was significantly elevated in RA patients compared to healthy normal controls with a highly statistically significant difference (P<0.001). The serum levels of CXCR3 were elevated in Long-standing RA more than early RA. Serum level of CXCR3 was only positively correlated with the duration of disease (r=0.540, p= >0.001) and combined treatment (r=0.296, p=0.022). ROC curves were plotted for prediction of serum CXCR3 in RA patients. The best cut-off value of 4.026 ng/mL serum CXCR3 that indicate the presence of early RA disease with 71.7% sensitivity and 70% specificity (p=0.005). Conclusion: Serum CXCR3 is an imperative predictive biomarker for the diagnosis of RA and is an indicator of early RA disease and endorses the established RA disease. | ||||
| Keywords | ||||
| Biomarker; Chemokine; Receptor; Prediction; Rheumatoid arthritis | ||||
|
Statistics Article View: 392 PDF Download: 255 |
||||
